Open Access

ARTICLE

3-epi-bufotalin suppresses the proliferation in colorectal cancer cells through the inhibition of the JAK1/STAT3 signaling pathway

SANHUA LI^1,2,#, QINGHONG KONG^1,2,#, XIAOKE ZHANG^1,2, XINTING ZHU^1,3, CHUNBO YU³, CHANGYAN YU^1,2, NIAN JIANG^1,2, JING HUI^1,2, LINGJIE MENG^1,2,*, YUN LIU^1,2,3,*

1 Guizhou Provincial College–Based Key Lab for Tumor Prevention and Treatment with Distinctive Medicines, Zunyi, 563000, China
2 Life Science Institute of Zunyi Medical University, Zunyi, 563000, China
3 School of Preclinical Medicine of Zunyi Medical University, Zunyi, 563000, China

* Corresponding Authors: LINGJIE MENG. Email: ; YUN LIU. Email:
# The authors contributed equally to the research

(This article belongs to the Special Issue: Recent Advancement in Cancer Molecular Signaling)

BIOCELL 2022, 46(11), 2425-2432. https://doi.org/10.32604/biocell.2022.019916

Received 24 October 2021; Accepted 06 April 2022; Issue published 07 July 2022

Abstract

Traditional Chinese medicine (TCM) has been increasingly employed in the last decades in China for both preventing and treating a variety of cancers. 3-epi-bufotalin is an active ingredient of TCM “Chanpi” with anti-tumor potential. However, the effect and mechanism of 3-epi-bufotalin on colorectal cancers were not well disclosed. The present study demonstrated that 3-epi-bufotalin could reduce viability, trigger apoptosis, and block the cell cycle at the G₂/M stage in colorectal cancer cell lines HT29, RKO, and COLO205 in vitro. Moreover, 3-epi-bufotalin inhibited the JAK1/STAT3 signaling pathway. These results indicated the anti-proliferation ability of 3-epi-bufotalin in colorectal cancer cells.

---

Keywords

---